Renal Cell Cancer (RCC): Making a Plethora of Drugs Understandable

EVENT DETAILS AND REGISTRATION

Date:December 01, 2016

Time: 05:30 PM - 08:00 PM (PT)

Location:Visitor Center, City of Hope, Duarte, CA

Event Is:

  1. Discuss the options for operative and minimally invasive surgical management of localized and metastatic renal cell cancer (mRCC).
  2. Review the molecular genetics and biology of renal cell cancer (RCC) and integrate predictive/prognostic markers into treatment decision-making  for patients who have mRCC.
  3. Analyze emerging clinical data evaluating the use of systemic, targeted, and immunomodulatory therapies for mRCC, either sequentially and/or in combination, and in the first-line and second-line settings.
  4. Profile and discuss common adverse effects associated with agents used to treat mRCC and develop strategies for managing these toxicities.
  5. Identify and implement strategies to individualize therapy and optimize therapeutic outcomes for the patient with mRCC.

Presenters:Clayton S. Lau, M.D. • Director, Urologic Oncology and Robotic Surgery Fellowship • Director, Prostate Cancer Program • Head, Retroperitoneal Surgery • Associate Clinical Professor, Department of Surgery • Director, Urology & Urologic Oncology Fe

ADDITIONAL DETAILS:

Objectives:

  1. Discuss the options for operative and minimally invasive surgical management of localized and metastatic renal cell cancer (mRCC).
  2. Review the molecular genetics and biology of renal cell cancer (RCC) and integrate predictive/prognostic markers into treatment decision-making  for patients who have mRCC.
  3. Analyze emerging clinical data evaluating the use of systemic, targeted, and immunomodulatory therapies for mRCC, either sequentially and/or in combination, and in the first-line and second-line settings.
  4. Profile and discuss common adverse effects associated with agents used to treat mRCC and develop strategies for managing these toxicities.
  5. Identify and implement strategies to individualize therapy and optimize therapeutic outcomes for the patient with mRCC.

Who should attend:

Medical Oncologists, Surgeons, Radiation Oncologists, Urologists, Internists, and other allied health care professionals who treat patients with renal cell cancer.

CME credits:1.5 - AMA PRA Category 1 CreditTM

R.S.V.P.: Click here to register

Web Link:https://cme.cityofhope.org/eventinfo_7392.html

Contact:

Continuing Medical Education Department